logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 12 of 12 Items
Showing 1 - 12 of 12 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Short Report

Diagnostic yield as an important metric for the evaluation of novel tuberculosis tests: rationale and guidance for future research

Broger T, Marx FM, Theron G, Marais BJ, Nicol MP,  et al.
2024-07-01 • Lancet Global Health
2024-07-01 • Lancet Global Health
Journal Article
|
Research

Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis

Gunasekera KS, Marcy O, Muñoz J, Lopez-Varela E, Sekadde MP,  et al.
2023-03-13 • Lancet Child and Adolescent Health
2023-03-13 • Lancet Child and Adolescent Health
BACKGROUND
Many children with pulmonary tuberculosis remain undiagnosed and untreated with related high morbidity and mortality. Recent advances in childhood tuberculosis algorithm d...
Journal Article
|
Research

Rifampicin resistance and mortality in patients hospitalised with HIV-associated tuberculosis

Spies R, Schutz C, Ward A, Balfour A, Shey M,  et al.
2022-09-27 • Southern African Journal of HIV Medicine
2022-09-27 • Southern African Journal of HIV Medicine
BACKGROUND
Patients with HIV and drug-resistant tuberculosis (TB) are at high risk of death.

OBJECTIVES
We investigated the association between rifampicin-resistant TB (...
Journal Article
|
Short Report

Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?

Cox HS, Hughes J, Black JM, Nicol MP
2018-03-13 • Lancet Infectious Diseases
2018-03-13 • Lancet Infectious Diseases
Treatment for drug-resistant tuberculosis is largely delivered through standardised, empirical combination regimens in low-resource, high-burden settings. However, individualised treatme...
Journal Article
|
Research

Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S,  et al.
2021-08-30 • Antimicrobial Agents and Chemotherapy
2021-08-30 • Antimicrobial Agents and Chemotherapy
Rifampicin mono-resistant TB (RMR-TB, rifampicin resistance and isoniazid susceptibility) constitutes 38% of all rifampicin-resistant TB (RR-TB) in South Africa and is increasing. We aim...
Journal Article
|
Research

Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study

Cox HS, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F,  et al.
2021-11-01 • Lancet Microbe
2021-11-01 • Lancet Microbe
BACKGROUND
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...
Journal Article
|
Research

Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study

Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E,  et al.
2011-04-19 • Lancet
2011-04-19 • Lancet
BACKGROUND: The Xpert MTB/RIF test (Cepheid, Sunnyvale, CA, USA) can detect tuberculosis and its multidrug-resistant form with very high sensitivity and specificity in controlled studies...
Journal Article
|
Research

Rifampicin-monoresistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S,  et al.
2021-10-18 • Antimicrobial Agents and Chemotherapy
2021-10-18 • Antimicrobial Agents and Chemotherapy
Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aime...
Journal Article
|
Research

Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study

Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A,  et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...
Journal Article
|
Research

Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial

Cox HS, Mbhele S, Mohess N, Whitelaw A, Muller O,  et al.
2014-11-25 • PLOS Medicine
2014-11-25 • PLOS Medicine
BACKGROUND
Xpert MTB/RIF is approved for use in tuberculosis (TB) and rifampicin-resistance diagnosis. However, data are limited on the impact of Xpert under routine conditions in se...
Journal Article
|
Letter

Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV

Kerkhoff AD, Sossen B, Schutz C, Reipold EI, Trollip AP,  et al.
2019-11-07 • European Respiratory Journal
2019-11-07 • European Respiratory Journal
Journal Article
|
Research

Disseminated Tuberculosis Among Hospitalised HIV Patients in South Africa: A Common Condition that Can Be Rapidly Diagnosed Using Urine-Based Assays

Kerkhoff AD, Barr DA, Schutz C, Burton R, Nicol MP,  et al.
2017-09-07 • Scientific Reports
2017-09-07 • Scientific Reports
HIV-associated disseminated TB (tuberculosis) has been under-recognised and poorly characterised. Blood culture is the gold-standard diagnostic test, but is expensive, slow, and may unde...